FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969983122> ?p ?o ?g. }

• W2969983122 endingPage "657" @default.
• W2969983122 startingPage "639" @default.
• W2969983122 abstract "This overview presents the updated European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ (CIS).To provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation and recommendations.A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines has been performed annually since the last published version in 2017. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries. Previous guidelines were updated, and the level of evidence and grade of recommendation were assigned.Tumours staged as Ta, T1, and/or CIS are grouped under the heading of NMIBC. Diagnosis depends on cystoscopy and histological evaluation of the tissue obtained by transurethral resection (TURB) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TURB is essential for the patient's prognosis and correct diagnosis. Where the initial resection is incomplete, where there is no muscle in the specimen, or where a T1 tumour is detected, a second TURB should be performed within 2-6 wk. The risks of both recurrence and progression may be estimated for individual patients using the European Organisation for Research and Treatment of Cancer (EORTC) scoring system. Stratification of patients into low-, intermediate-, and high-risk groups is pivotal to the recommendation of adjuvant treatment. In patients with tumours presumed to be at a low risk and in those presumed to be at an intermediate risk with a low previous recurrence rate and an expected EORTC recurrence score of <5, one immediate chemotherapy instillation is recommended. Patients with intermediate-risk tumours should receive 1 yr of full-dose bacillus Calmette-Guérin (BCG) intravesical immunotherapy or instillations of chemotherapy for a maximum of 1 yr. In patients with high-risk tumours, full-dose intravesical BCG for 1-3 yr is indicated. In patients at the highest risk of tumour progression, immediate radical cystectomy should be considered. Cystectomy is recommended in BCG-unresponsive tumours. The extended version of the guidelines is available at the EAU website: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/.These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice.The European Association of Urology Non-muscle-invasive Bladder Cancer (NMIBC) Panel has released an updated version of their guidelines, which contains information on classification, risk factors, diagnosis, prognostic factors, and treatment of NMIBC. The recommendations are based on the current literature (until the end of 2018), with emphasis on high-level data from randomised clinical trials and meta-analyses. Stratification of patients into low-, intermediate-, and high-risk groups is essential for deciding appropriate use of adjuvant intravesical chemotherapy or bacillus Calmette-Guérin (BCG) instillations. Surgical removal of the bladder should be considered in case of BCG-unresponsive tumours or in NMIBCs with the highest risk of progression." @default.
• W2969983122 created "2019-08-29" @default.
• W2969983122 creator A5004584899 @default.
• W2969983122 creator A5016314807 @default.
• W2969983122 creator A5019083341 @default.
• W2969983122 creator A5030019301 @default.
• W2969983122 creator A5033224206 @default.
• W2969983122 creator A5042309401 @default.
• W2969983122 creator A5046873085 @default.
• W2969983122 creator A5051226598 @default.
• W2969983122 creator A5056088520 @default.
• W2969983122 creator A5058168074 @default.
• W2969983122 creator A5059061843 @default.
• W2969983122 creator A5063195568 @default.
• W2969983122 creator A5064914239 @default.
• W2969983122 creator A5069476166 @default.
• W2969983122 creator A5077999992 @default.
• W2969983122 creator A5080636670 @default.
• W2969983122 creator A5081888569 @default.
• W2969983122 creator A5088487307 @default.
• W2969983122 date "2019-11-01" @default.
• W2969983122 modified "2023-10-14" @default.
• W2969983122 title "European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update" @default.
• W2969983122 cites W1423791052 @default.
• W2969983122 cites W1533663316 @default.
• W2969983122 cites W1560239325 @default.
• W2969983122 cites W1572827793 @default.
• W2969983122 cites W1578051988 @default.
• W2969983122 cites W1581418365 @default.
• W2969983122 cites W1586356187 @default.
• W2969983122 cites W1597031372 @default.
• W2969983122 cites W1744848835 @default.
• W2969983122 cites W1754265771 @default.
• W2969983122 cites W1785893379 @default.
• W2969983122 cites W1788729872 @default.
• W2969983122 cites W1867431668 @default.
• W2969983122 cites W1965580073 @default.
• W2969983122 cites W1967513395 @default.
• W2969983122 cites W1980582829 @default.
• W2969983122 cites W1986277645 @default.
• W2969983122 cites W1987417755 @default.
• W2969983122 cites W1993844636 @default.
• W2969983122 cites W2002045993 @default.
• W2969983122 cites W2004457875 @default.
• W2969983122 cites W2007270357 @default.
• W2969983122 cites W2013009938 @default.
• W2969983122 cites W2013720617 @default.
• W2969983122 cites W2013938985 @default.
• W2969983122 cites W2014448379 @default.
• W2969983122 cites W2015469438 @default.
• W2969983122 cites W2017306423 @default.
• W2969983122 cites W2025042153 @default.
• W2969983122 cites W2028758612 @default.
• W2969983122 cites W2030874794 @default.
• W2969983122 cites W2035062922 @default.
• W2969983122 cites W2039161970 @default.
• W2969983122 cites W2039218197 @default.
• W2969983122 cites W2051973574 @default.
• W2969983122 cites W2056319752 @default.
• W2969983122 cites W2058389484 @default.
• W2969983122 cites W2065151446 @default.
• W2969983122 cites W2065244452 @default.
• W2969983122 cites W2066066551 @default.
• W2969983122 cites W2070491670 @default.
• W2969983122 cites W2072358888 @default.
• W2969983122 cites W2073887720 @default.
• W2969983122 cites W2076954194 @default.
• W2969983122 cites W2077182928 @default.
• W2969983122 cites W2077884368 @default.
• W2969983122 cites W2078228026 @default.
• W2969983122 cites W2078530848 @default.
• W2969983122 cites W2079542321 @default.
• W2969983122 cites W2080696159 @default.
• W2969983122 cites W2085910362 @default.
• W2969983122 cites W2089484962 @default.
• W2969983122 cites W2090796716 @default.
• W2969983122 cites W2097742528 @default.
• W2969983122 cites W2098614234 @default.
• W2969983122 cites W2104570929 @default.
• W2969983122 cites W2108974158 @default.
• W2969983122 cites W2110973315 @default.
• W2969983122 cites W2111078038 @default.
• W2969983122 cites W2111419267 @default.
• W2969983122 cites W2112673969 @default.
• W2969983122 cites W2116195839 @default.
• W2969983122 cites W2116299167 @default.
• W2969983122 cites W2123614023 @default.
• W2969983122 cites W2126051101 @default.
• W2969983122 cites W2126233109 @default.
• W2969983122 cites W2126903040 @default.
• W2969983122 cites W2129198262 @default.
• W2969983122 cites W2132294629 @default.
• W2969983122 cites W2132319960 @default.
• W2969983122 cites W2132528079 @default.
• W2969983122 cites W2134589781 @default.
• W2969983122 cites W2134721581 @default.
• W2969983122 cites W2134734117 @default.
• W2969983122 cites W2134906789 @default.

• next